OBJECT: World Health Organization Grade 2 meningiomas are aggressive tumors associated with a high recurrence rate leading to repeated surgical procedures, which can seriously worsen a patient's neurological status. Although radiosurgery is an increasingly popular technique, its role in the management of Grade 2 meningiomas has yet to be defined. In this study the authors aimed to evaluate radiosurgery in achieving control of proven tumor progression occurring after resection of Grade 2 meningioma. METHODS: This retrospective study included consecutive patients who, between 2000 and 2012, had undergone radiosurgery for radiologically proven progression of a previously surgically treated Grade 2 meningioma. RESULTS: Twenty-seven patients were eligible for analysis. There were 9 men and 18 women with a mean age of 59 years. The mean radiation dose was 15.2 Gy (range 12-21 Gy), and the mean target volume was 5.4 cm(3) (range 0.194-14.2 cm(3)). Thirty-four radiosurgical procedures were performed in the 27 patients. The mean progression-free survival after radiosurgery was 32.4 months among those with progression in a target irradiated volume and 26.4 months among those with progression in any intracranial meninges. With a mean follow-up of 56.4 months (range 12-108 months), the 12-, 24-, and 36-month actuarial local control rates for all patients were 75%, 52%, and 40%, respectively, and the regional control rates were 75%, 48%, and 33%. A single case of transient hemiparesis completely resolved without sequelae. CONCLUSIONS: Radiosurgery appears to be a safe and effective treatment for the local control of delayed progression after resection of a Grade 2 meningioma. Higher radiation doses similar to those applied for malignant tumors should be recommended when possible.
OBJECT: World Health Organization Grade 2 meningiomas are aggressive tumors associated with a high recurrence rate leading to repeated surgical procedures, which can seriously worsen a patient's neurological status. Although radiosurgery is an increasingly popular technique, its role in the management of Grade 2 meningiomas has yet to be defined. In this study the authors aimed to evaluate radiosurgery in achieving control of proven tumor progression occurring after resection of Grade 2 meningioma. METHODS: This retrospective study included consecutive patients who, between 2000 and 2012, had undergone radiosurgery for radiologically proven progression of a previously surgically treated Grade 2 meningioma. RESULTS: Twenty-seven patients were eligible for analysis. There were 9 men and 18 women with a mean age of 59 years. The mean radiation dose was 15.2 Gy (range 12-21 Gy), and the mean target volume was 5.4 cm(3) (range 0.194-14.2 cm(3)). Thirty-four radiosurgical procedures were performed in the 27 patients. The mean progression-free survival after radiosurgery was 32.4 months among those with progression in a target irradiated volume and 26.4 months among those with progression in any intracranial meninges. With a mean follow-up of 56.4 months (range 12-108 months), the 12-, 24-, and 36-month actuarial local control rates for all patients were 75%, 52%, and 40%, respectively, and the regional control rates were 75%, 48%, and 33%. A single case of transient hemiparesis completely resolved without sequelae. CONCLUSIONS: Radiosurgery appears to be a safe and effective treatment for the local control of delayed progression after resection of a Grade 2 meningioma. Higher radiation doses similar to those applied for malignant tumors should be recommended when possible.
Authors: Arbaz A Momin; Jianning Shao; Pranay Soni; João Paulo Almeida; John H Suh; Erin S Murphy; Samuel T Chao; Lilyana Angelov; Alireza M Mohammadi; Gene H Barnett; Pablo F Recinos; Varun R Kshettry Journal: J Neurooncol Date: 2021-02-15 Impact factor: 4.130
Authors: Hirotaka Hasegawa; Kunal Vakharia; Michael J Link; Scott L Stafford; Paul D Brown; Ian F Parney; Terry C Burns; Elizabeth S Yan; Anita Mahajan; Nadia N Laack; Bruce E Pollock Journal: J Neurooncol Date: 2021-10-27 Impact factor: 4.130
Authors: Tamer Refaat; Michelle Gentile; Sean Sachdev; Prarthana Dalal; Anish Butala; Stanley Gutiontov; Irene Helenowksi; Plato Lee; Vythialinga Sathiaseelan; Orin Bloch; James Chandler; John A Kalapurakal Journal: J Neurol Surg B Skull Base Date: 2017-02-01
Authors: Ciro Mastantuoni; Luigi Maria Cavallo; Felice Esposito; Elena d'Avella; Oreste de Divitiis; Teresa Somma; Andrea Bocchino; Gianluca Lorenzo Fabozzi; Paolo Cappabianca; Domenico Solari Journal: Cancers (Basel) Date: 2022-06-10 Impact factor: 6.575
Authors: F Meniai-Merzouki; V Bernier-Chastagner; J Geffrelot; E Tresch; T Lacornerie; B Coche-Dequeant; E Lartigau; D Pasquier Journal: Sci Rep Date: 2018-09-12 Impact factor: 4.379